Clear guidance from global policymakers signalling that CD4 measurement is the preferred tool for detection of AHD, and from national HIV departments indicating the utility of CD4 measurement for clinical care and surveillance, would increase market confidence.[10] Similar policy-driven market stimulation has successfully accelerated the global scale-up of other diagnostics, such as rapid point-of-care HIV testing and the GeneXpert MTB/RIF platform for tuberculosis, demonstrating that coordinated policy and procurement strategies can drive availability and uptake in resource-limited settings. The gene discussed is CD4; the disease is tuberculosis.